A detailed history of Summit Financial Strategies, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Summit Financial Strategies, Inc. holds 5,105 shares of ABBV stock, worth $858,354. This represents 0.14% of its overall portfolio holdings.

Number of Shares
5,105
Previous 6,249 18.31%
Holding current value
$858,354
Previous $968,000 4.03%
% of portfolio
0.14%
Previous 0.15%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $182,834 - $208,322
-1,144 Reduced 18.31%
5,105 $929,000
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $19,264 - $21,695
-140 Reduced 2.19%
6,249 $968,000
Q3 2023

Oct 24, 2023

SELL
$133.59 - $154.65 $34,199 - $39,590
-256 Reduced 3.85%
6,389 $952,000
Q2 2023

Jul 21, 2023

BUY
$132.51 - $164.9 $5,432 - $6,760
41 Added 0.62%
6,645 $895,000
Q1 2023

Apr 21, 2023

SELL
$144.61 - $166.54 $4,482 - $5,162
-31 Reduced 0.47%
6,604 $1.05 Million
Q4 2022

Jan 20, 2023

SELL
$138.31 - $165.87 $38,311 - $45,945
-277 Reduced 4.01%
6,635 $0
Q3 2022

Oct 21, 2022

BUY
$134.21 - $153.93 $36,102 - $41,407
269 Added 4.05%
6,912 $928,000
Q2 2022

Jul 25, 2022

BUY
$137.62 - $174.96 $48,442 - $61,585
352 Added 5.6%
6,643 $1.02 Million
Q1 2022

May 04, 2022

SELL
$131.98 - $163.75 $72,193 - $89,571
-547 Reduced 8.0%
6,291 $1.02 Million
Q2 2021

Aug 11, 2021

BUY
$105.21 - $117.21 $281,015 - $313,067
2,671 Added 64.1%
6,838 $770,000
Q1 2021

May 11, 2021

SELL
$102.3 - $112.62 $93,297 - $102,709
-912 Reduced 17.96%
4,167 $451,000
Q4 2020

Feb 05, 2021

SELL
$80.49 - $108.67 $39,279 - $53,030
-488 Reduced 8.77%
5,079 $544,000
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $343 - $403
4 Added 0.07%
5,567 $488,000
Q2 2020

Jul 31, 2020

BUY
$73.37 - $98.18 $27,146 - $36,326
370 Added 7.12%
5,563 $546,000
Q1 2020

May 11, 2020

SELL
$64.5 - $97.79 $22,575 - $34,226
-350 Reduced 6.31%
5,193 $396,000
Q4 2019

Feb 11, 2020

BUY
$72.13 - $90.25 $4,760 - $5,956
66 Added 1.21%
5,543 $491,000
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $39,425 - $47,400
-626 Reduced 10.26%
5,477 $415,000
Q2 2019

Aug 08, 2019

SELL
$65.7 - $83.98 $10,971 - $14,024
-167 Reduced 2.66%
6,103 $444,000
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $1,157 - $1,361
-15 Reduced 0.24%
6,270 $505,000
Q3 2018

Nov 09, 2018

SELL
$88.91 - $98.84 $223,253 - $248,187
-2,511 Reduced 28.55%
6,285 $594,000
Q2 2018

Aug 06, 2018

BUY
$89.78 - $106.23 $300,403 - $355,445
3,346 Added 61.39%
8,796 $815,000
Q1 2018

May 14, 2018

BUY
$92.01 - $123.21 $154,116 - $206,376
1,675 Added 44.37%
5,450 $516,000
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $263,683 - $336,805
3,775
3,775 $335,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Summit Financial Strategies, Inc. Portfolio

Follow Summit Financial Strategies, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Financial Strategies, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Summit Financial Strategies, Inc. with notifications on news.